JP2007519742A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007519742A5 JP2007519742A5 JP2006551500A JP2006551500A JP2007519742A5 JP 2007519742 A5 JP2007519742 A5 JP 2007519742A5 JP 2006551500 A JP2006551500 A JP 2006551500A JP 2006551500 A JP2006551500 A JP 2006551500A JP 2007519742 A5 JP2007519742 A5 JP 2007519742A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- ring
- compound
- optionally substituted
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 46
- 125000000217 alkyl group Chemical group 0.000 claims 36
- -1 phenyloxy, benzyl Chemical group 0.000 claims 24
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 15
- 125000005842 heteroatom Chemical group 0.000 claims 13
- 229910052739 hydrogen Inorganic materials 0.000 claims 13
- 239000001257 hydrogen Substances 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 229910052757 nitrogen Inorganic materials 0.000 claims 11
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 10
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 8
- 229910052799 carbon Inorganic materials 0.000 claims 8
- 125000002950 monocyclic group Chemical group 0.000 claims 8
- 239000001301 oxygen Substances 0.000 claims 8
- 239000011593 sulfur Substances 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 150000002431 hydrogen Chemical class 0.000 claims 7
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000030507 AIDS Diseases 0.000 claims 6
- 125000004429 atom Chemical group 0.000 claims 6
- 229910052794 bromium Inorganic materials 0.000 claims 6
- 125000004432 carbon atom Chemical group C* 0.000 claims 6
- 125000003226 pyrazolyl group Chemical group 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 229920006395 saturated elastomer Polymers 0.000 claims 6
- 229940124597 therapeutic agent Drugs 0.000 claims 6
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 229910052731 fluorine Inorganic materials 0.000 claims 5
- 125000002541 furyl group Chemical group 0.000 claims 5
- 229910052740 iodine Inorganic materials 0.000 claims 5
- 230000001404 mediated effect Effects 0.000 claims 5
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims 5
- 229930192474 thiophene Natural products 0.000 claims 5
- 125000006413 ring segment Chemical group 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 3
- 230000003463 hyperproliferative effect Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 206010025135 lupus erythematosus Diseases 0.000 claims 3
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 230000002062 proliferating effect Effects 0.000 claims 3
- 206010039083 rhinitis Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 125000001931 aliphatic group Chemical group 0.000 claims 2
- 239000012472 biological sample Substances 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000035939 Alveolitis allergic Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000036487 Arthropathies Diseases 0.000 claims 1
- 201000008283 Atrophic Rhinitis Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010014950 Eosinophilia Diseases 0.000 claims 1
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims 1
- 206010014989 Epidermolysis bullosa Diseases 0.000 claims 1
- 206010015150 Erythema Diseases 0.000 claims 1
- 208000027445 Farmer Lung Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000003838 Idiopathic interstitial pneumonia Diseases 0.000 claims 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 1
- 208000012659 Joint disease Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000033464 Reiter syndrome Diseases 0.000 claims 1
- 206010039088 Rhinitis atrophic Diseases 0.000 claims 1
- 208000036284 Rhinitis seasonal Diseases 0.000 claims 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims 1
- 208000009359 Sezary Syndrome Diseases 0.000 claims 1
- 208000021388 Sezary disease Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000024780 Urticaria Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 238000002399 angioplasty Methods 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 125000002619 bicyclic group Chemical group 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 201000009151 chronic rhinitis Diseases 0.000 claims 1
- 210000004087 cornea Anatomy 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 claims 1
- 231100000321 erythema Toxicity 0.000 claims 1
- 208000022195 farmer lung disease Diseases 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000011486 lichen planus Diseases 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 208000008585 mastocytosis Diseases 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 201000005962 mycosis fungoides Diseases 0.000 claims 1
- 201000009240 nasopharyngitis Diseases 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 208000002574 reactive arthritis Diseases 0.000 claims 1
- 208000037803 restenosis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 208000008742 seborrheic dermatitis Diseases 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 0 CC(N12)=C(*)C(**)=NC1=NC(*)=C(*)C2=O Chemical compound CC(N12)=C(*)C(**)=NC1=NC(*)=C(*)C2=O 0.000 description 1
- UCBZYLNJRPNAKV-UHFFFAOYSA-N CC(N12)=CC(Nc3cc(C4CC4)n[nH]3)=NC1=Nc1ccccc1C2=O Chemical compound CC(N12)=CC(Nc3cc(C4CC4)n[nH]3)=NC1=Nc1ccccc1C2=O UCBZYLNJRPNAKV-UHFFFAOYSA-N 0.000 description 1
- AEXWWGYBXSBBBX-UHFFFAOYSA-N Cc1n[nH]c(NC(c(cccc2)c2N23)=NC2=Nc2cc(N)ccc2C3=O)c1 Chemical compound Cc1n[nH]c(NC(c(cccc2)c2N23)=NC2=Nc2cc(N)ccc2C3=O)c1 AEXWWGYBXSBBBX-UHFFFAOYSA-N 0.000 description 1
- OODYCAJLBKRODK-JRUCOHCHSA-N N/C(/NC(c(cccc1)c1N12)=NC1=Nc1ccccc1C2=O)=C\C(c1ccccc1)=N Chemical compound N/C(/NC(c(cccc1)c1N12)=NC1=Nc1ccccc1C2=O)=C\C(c1ccccc1)=N OODYCAJLBKRODK-JRUCOHCHSA-N 0.000 description 1
- FPLXBPGPGOATHB-UHFFFAOYSA-N Nc(cc1N=C(N2C=C3)N=C3Nc3cc(C4CC4)n[nH]3)ccc1C2=O Chemical compound Nc(cc1N=C(N2C=C3)N=C3Nc3cc(C4CC4)n[nH]3)ccc1C2=O FPLXBPGPGOATHB-UHFFFAOYSA-N 0.000 description 1
- MDEGEGZLYAKXIQ-UHFFFAOYSA-N Nc(cc1N=C(N2c3c4cccc3)N=C4Nc3n[nH]c(C4CC4)c3)ccc1C2=O Chemical compound Nc(cc1N=C(N2c3c4cccc3)N=C4Nc3n[nH]c(C4CC4)c3)ccc1C2=O MDEGEGZLYAKXIQ-UHFFFAOYSA-N 0.000 description 1
- JHTFTJHZPGOBPS-UHFFFAOYSA-N O=C1N(c(cccc2)c2C(Nc2cc(C3CC3)n[nH]2)=N2)C2=Nc2ccccc12 Chemical compound O=C1N(c(cccc2)c2C(Nc2cc(C3CC3)n[nH]2)=N2)C2=Nc2ccccc12 JHTFTJHZPGOBPS-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US53917604P | 2004-01-26 | 2004-01-26 | |
| PCT/US2005/002725 WO2005095406A1 (en) | 2004-01-26 | 2005-01-26 | Compositions useful as inhibitors of protein kinases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011045758A Division JP2011105775A (ja) | 2004-01-26 | 2011-03-02 | プロテインキナーゼの阻害剤として有用な組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007519742A JP2007519742A (ja) | 2007-07-19 |
| JP2007519742A5 true JP2007519742A5 (https=) | 2008-02-28 |
Family
ID=34960536
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006551500A Pending JP2007519742A (ja) | 2004-01-26 | 2005-01-26 | プロテインキナーゼの阻害剤として有用な組成物 |
| JP2011045758A Withdrawn JP2011105775A (ja) | 2004-01-26 | 2011-03-02 | プロテインキナーゼの阻害剤として有用な組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011045758A Withdrawn JP2011105775A (ja) | 2004-01-26 | 2011-03-02 | プロテインキナーゼの阻害剤として有用な組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7855214B2 (https=) |
| EP (1) | EP1716151A1 (https=) |
| JP (2) | JP2007519742A (https=) |
| CN (1) | CN1934113B (https=) |
| AU (1) | AU2005228845A1 (https=) |
| CA (1) | CA2554551A1 (https=) |
| WO (1) | WO2005095406A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20080098490A (ko) * | 2006-01-13 | 2008-11-10 | 파마시클릭스, 인코포레이티드 | 티로신 키나제 억제제 및 이의 용도 |
| WO2007136790A2 (en) * | 2006-05-18 | 2007-11-29 | Mannkind Corporation | Intracellular kinase inhibitors |
| DK2526933T3 (en) * | 2006-09-22 | 2015-05-18 | Pharmacyclics Inc | Inhibitors of Bruton's tyrosine kinase |
| US20120101114A1 (en) | 2007-03-28 | 2012-04-26 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| US20090301928A1 (en) * | 2008-06-05 | 2009-12-10 | United Comb & Novelty Corporation | Packaging For Lipped Containers |
| CA2730930C (en) | 2008-07-16 | 2015-01-13 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
| CA3007787C (en) | 2010-06-03 | 2020-03-10 | Pharmacyclics Llc | The use of inhibitors of bruton's tyrosine kinase (btk) |
| WO2012158913A2 (en) | 2011-05-17 | 2012-11-22 | Discoverybiomed Inc. | Treating protein folding disorders with small molecule cftr correctors |
| JP2014520863A (ja) | 2011-07-13 | 2014-08-25 | ファーマサイクリックス，インク． | Ｂｒｕｔｏｎ型チロシンキナーゼの阻害剤 |
| US8377946B1 (en) | 2011-12-30 | 2013-02-19 | Pharmacyclics, Inc. | Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors |
| WO2013153539A1 (en) | 2012-04-13 | 2013-10-17 | Glenmark Pharmaceuticals S.A. | Tricyclic compounds as tec kinase inhibitors |
| KR20210033067A (ko) | 2012-06-04 | 2021-03-25 | 파마싸이클릭스 엘엘씨 | 브루톤 타이로신 키나아제 저해제의 결정 형태 |
| CN104704129A (zh) | 2012-07-24 | 2015-06-10 | 药品循环公司 | 与对布鲁顿酪氨酸激酶(btk)抑制剂的抗性相关的突变 |
| EA201590855A1 (ru) | 2012-11-15 | 2015-11-30 | Фармасайкликс, Инк. | Соединения пирролопиримидина как ингибиторы киназ |
| AU2013348018A1 (en) | 2012-11-20 | 2015-06-04 | Discoverybiomed, Inc. | Small molecule CFTR correctors |
| EP2922853A4 (en) | 2012-11-20 | 2016-11-23 | Discoverybiomed Inc | SMALL MOLECULE BICYCLIC AND TRICYCLIC CFTR CORRECTING DEVICES |
| JP6800750B2 (ja) | 2013-08-02 | 2020-12-16 | ファーマサイクリックス エルエルシー | 固形腫瘍の処置方法 |
| US9415050B2 (en) | 2013-08-12 | 2016-08-16 | Pharmacyclics Llc | Methods for the treatment of HER2 amplified cancer |
| BR112016006978A2 (pt) | 2013-09-30 | 2017-08-01 | Pharmacyclics Llc | inibidores de tirosina quinase de bruton |
| JP2016538270A (ja) | 2013-10-25 | 2016-12-08 | ファーマサイクリックス エルエルシー | 移植片対宿主病を処置し予防する方法 |
| US9885086B2 (en) | 2014-03-20 | 2018-02-06 | Pharmacyclics Llc | Phospholipase C gamma 2 and resistance associated mutations |
| AU2015296215A1 (en) | 2014-08-01 | 2017-03-23 | Pharmacyclics Llc | Inhibitors of bruton's tyrosine kinase |
| KR20170033358A (ko) | 2014-08-07 | 2017-03-24 | 파마싸이클릭스 엘엘씨 | 브루톤 티로신 키나아제 저해제의 신규한 제제 |
| IL315294A (en) | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1268170A1 (ru) * | 1974-01-04 | 1986-11-07 | Киевский научно-исследовательский институт фармакологии и токсикологии | Антиревматическое средство "пиримидант |
| SU1323560A1 (ru) * | 1981-08-14 | 1987-07-15 | Киевский научно-исследовательский институт фармакологии и токсикологии | Хлоргидраты эфиров 2- /О-карбоксифениламино/-6-пиримидо-[2,1-в]-хиназолона-6,про вл ющие противовоспалительную,анальгезирующую и жаропонижающую активность |
| SU1174433A1 (ru) * | 1981-10-19 | 1985-08-23 | Киевский научно-исследовательский институт фармакологии и токсикологии | Соли-2-( @ -карбоксифениламино)-6 @ -пиримидо @ 2,1- @ хиназолона-6,про вл ющие противовоспалительную активность |
| US4455312A (en) | 1982-08-19 | 1984-06-19 | Portnyagina Vera A | 2-(o-Carboxyphenylamino)-6H-pyrimido(2,1-b)-quinazolone-6 and derivatives thereof, and application as antiphlogistics |
| GB2125785B (en) * | 1982-08-20 | 1986-07-23 | Ki Nii Farmakologii Toksikolog | 2-(o-carboxyphenylamino)-6h-pyrimido (2 1-b)-quinazolone -6 and derivatives thereof |
| JPS5955884A (ja) * | 1982-09-14 | 1984-03-31 | キエフスキ−・ナウチノ−イスレドワ−チエルスキ−・インスチツ−ト・フアルマコロギイ・イ・トクシコロギイ | ２−（Ｏ−カルボキシフエニルアミノ）−６Ｈ−ピリミド（２，１−ｂ）−キナゾロン−６およびその誘導体、製法および使用 |
| CN1891693A (zh) * | 2000-01-24 | 2007-01-10 | 基纳西亚股份有限公司 | 用于治疗的吗啉代基取代的化合物 |
| DE60332433D1 (de) * | 2002-03-15 | 2010-06-17 | Vertex Pharma | Azolylaminoazine als proteinkinasehemmer |
-
2005
- 2005-01-26 AU AU2005228845A patent/AU2005228845A1/en not_active Abandoned
- 2005-01-26 WO PCT/US2005/002725 patent/WO2005095406A1/en not_active Ceased
- 2005-01-26 CN CN2005800089989A patent/CN1934113B/zh not_active Expired - Fee Related
- 2005-01-26 CA CA002554551A patent/CA2554551A1/en not_active Abandoned
- 2005-01-26 JP JP2006551500A patent/JP2007519742A/ja active Pending
- 2005-01-26 EP EP05712244A patent/EP1716151A1/en not_active Withdrawn
- 2005-01-26 US US11/046,664 patent/US7855214B2/en not_active Expired - Fee Related
-
2011
- 2011-03-02 JP JP2011045758A patent/JP2011105775A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007519742A5 (https=) | ||
| JP7374955B2 (ja) | 置換されたジアミノカルボキサミドおよびジアミノカルボニトリルピリミジン、その組成物、ならびに、それを用いた治療方法 | |
| JP7355758B2 (ja) | ケモカイン受容体調節剤及びその使用 | |
| JP7328987B2 (ja) | Ｉｉ型ｉｒａｋ阻害剤としてのヘテロアリール化合物及びその使用 | |
| CN115843272B (zh) | Nek7激酶的抑制剂 | |
| EP3204386B1 (en) | Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith | |
| TWI495637B (zh) | 用作單醯基甘油脂肪酶抑制劑之雜芳族及芳族六氫吡基吖丁啶基醯胺（一） | |
| TW201925187A (zh) | 經碸吡啶烷基醯胺取代之雜芳基化合物 | |
| US20110288081A1 (en) | Pyrimidine compounds and uses thereof | |
| JP2009536617A5 (https=) | ||
| MXPA04005181A (es) | Compuestos de pirimidina. | |
| JP2004520423A5 (https=) | ||
| JP6768838B2 (ja) | Ｒａｆキナーゼおよび血管内皮成長因子受容体を阻害するピリジン誘導体、この製造方法、これを含む薬剤学的組成物およびこの用途 | |
| JP2008513352A5 (https=) | ||
| JP4275947B2 (ja) | 三環式化合物およびその使用 | |
| JP6235029B2 (ja) | １ｈ−インドール−３−カルボキサミド誘導体およびｐ２ｙ１２拮抗薬としてのその使用 | |
| JP4108260B2 (ja) | 置換芳香環化合物、その製造法および用途 | |
| WO2025133961A1 (en) | Nitrogen-containing heteroaryl compounds for the treatment of chronic diseases | |
| KR101663543B1 (ko) | 부스피론 유도체 및 이를 함유하는 약학 조성물 | |
| JPS60158183A (ja) | １，４‐ジヒドロピラジン類 | |
| CN101277961A (zh) | 作为lfa-1调节剂的四氢吡咯里嗪酮化合物 | |
| HK1069824A (en) | Tricyclic compounds and their uses |